Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 6, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for February 4, 2007 Subscribe to this News Feed      
 

Citra Anticoagulants Announces CE Mark Approval for noClot-400™ Anticoagulant Citrate Dextrose Solution, Solution A, ACD-A, U.S.P., 4 Milliliters

Citra Anticoagulants, Inc. announces that noClot-400™ Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., 4 milliliters known as ACD-A, has CE mark approval for use in the extracorporeal blood processing with Autologous Platelet Rich Plasma (PRP) Systems in the production of platelet rich plasma.

Braintree, MA (PRWEB) February 4, 2007 -- Citra Anticoagulants, Inc. announces that noClot-400™ Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., 4 milliliters known as ACD-A, has CE mark approval for use in the extracorporeal blood processing with Autologous Platelet Rich Plasma (PRP) Systems in the production of platelet rich plasma. noClot brand anticoagulants are the anticoagulants of choice to prevent clotting of the whole blood during extracorporeal blood processing with Autologous PRP Systems.

This regulatory achievement clears the way for Citra Anticoagulants to market this product throughout the European Union. It also allows our customers to include this product in kits that they market and distribute throughout the Eurpoean Union. noClot-400 joins its sister product noClot-50™ and is marketed and distributed exclusively by Citra Anticoagulants, Inc.

noClot-400 is a United States Pharmacopeia formulated product containing 4 milliliters of ACD-A. noClot brand anticoagulants prevent the coagulation of blood by virtue of their citrate ion's ability to chelate the ionized calcium present in blood to form a non-ionized calcium-citrate complex. When the total dose of citrate ions is greater than the total amount of ionized calcium, blood clotting is prevented.

About Citra Anticoagulants

Headquartered in Braintree, Massachusetts, Citra Anticoagulants, Inc. markets and distributes a multitude of citrate-based anticoagulants to the worldwide medical arena. For more about Citra and our products, visit our website at www.CitraAnticoagulants.com.

Contact:
Citra Anticoagulants, Inc.
Ronald H. Lewis, Ph.D., President
Adrienne Summers, Team Customer
Tel: 781-848-2174
800-299-3411(USA only)
Fax: 781-848-6781

###

OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
ADRIENNE SUMMERS
Citra Anticoagulants, Inc.
800-299-3411
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright